Evaxion Biotech (EVAX) Fireside Chat summary

Introduction and agenda

• Discussion focused on AI-driven vaccine development, business strategy, and partnerships, with insights from the CEO and CSO.

• Covered recent clinical progress, financial updates, and future pipeline plans.

Background and experience of the speaker

• CEO highlighted the company's 15-year head start in AI-driven immunology, founded as an AI-first company in 2008.

• Management team has strengthened the balance sheet and built strong business development relationships over the past 18–24 months.

Current industry trends

• AI-based drug design is revolutionizing vaccine development, enabling faster, cheaper, and more accurate target identification.

• Growing interest in precision and personalized cancer vaccines, with strong scientific momentum in the field.

• Political changes and public skepticism toward vaccines create short-term turbulence but do not alter long-term industry priorities.